Arasanz et al79 recently confirmed that systemic expansion of highly differentiated CD28−CD4+ T lymphocytes (CD4+THD) was a potential biomarker of HPD and associated with poor clinical outcomes in NSCLC patients receiving immunotherapy. The gene discussed is CD4; the disease is non-small cell lung carcinoma.